APA

Buchanan S. G., Hendle J., Lee P. S., Smith C. R., Bounaud P., Jessen K. A., Tang C. M., Huser N. H., Felce J. D., Froning K. J., Peterman M. C., Aubol B. E., Gessert S. F., Sauder J. M., Schwinn K. D., Russell M., Rooney I. A., Adams J., Leon B. C., Do T. H., Blaney J. M., Sprengeler P. A., Thompson D. A., Smyth L., Pelletier L. A., Atwell S., Holme K., Wasserman S. R., Emtage S., Burley S. K. & Reich S. H. (20100324). SGX523 is an exquisitely selective, ATP-competitive inhibitor of the MET receptor tyrosine kinase with antitumor activity in vivo. : Molecular cancer therapeutics.

Chicago

Buchanan Sean G, Hendle Jorg, Lee Patrick S, Smith Christopher R, Bounaud Pierre-Yves, Jessen Katti A, Tang Crystal M, Huser Nanni H, Felce Jeremy D, Froning Karen J, Peterman Marshall C, Aubol Brandon E, Gessert Steve F, Sauder J Michael, Schwinn Kenneth D, Russell Marijane, Rooney Isabelle A, Adams Jason, Leon Barbara C, Do Tuan H, Blaney Jeff M, Sprengeler Paul A, Thompson Devon A, Smyth Lydia, Pelletier Laura A, Atwell Shane, Holme Kevin, Wasserman Stephen R, Emtage Spencer, Burley Stephen K and Reich Siegfried H. 20100324. SGX523 is an exquisitely selective, ATP-competitive inhibitor of the MET receptor tyrosine kinase with antitumor activity in vivo. : Molecular cancer therapeutics.

Harvard

Buchanan S. G., Hendle J., Lee P. S., Smith C. R., Bounaud P., Jessen K. A., Tang C. M., Huser N. H., Felce J. D., Froning K. J., Peterman M. C., Aubol B. E., Gessert S. F., Sauder J. M., Schwinn K. D., Russell M., Rooney I. A., Adams J., Leon B. C., Do T. H., Blaney J. M., Sprengeler P. A., Thompson D. A., Smyth L., Pelletier L. A., Atwell S., Holme K., Wasserman S. R., Emtage S., Burley S. K. and Reich S. H. (20100324). SGX523 is an exquisitely selective, ATP-competitive inhibitor of the MET receptor tyrosine kinase with antitumor activity in vivo. : Molecular cancer therapeutics.

MLA

Buchanan Sean G, Hendle Jorg, Lee Patrick S, Smith Christopher R, Bounaud Pierre-Yves, Jessen Katti A, Tang Crystal M, Huser Nanni H, Felce Jeremy D, Froning Karen J, Peterman Marshall C, Aubol Brandon E, Gessert Steve F, Sauder J Michael, Schwinn Kenneth D, Russell Marijane, Rooney Isabelle A, Adams Jason, Leon Barbara C, Do Tuan H, Blaney Jeff M, Sprengeler Paul A, Thompson Devon A, Smyth Lydia, Pelletier Laura A, Atwell Shane, Holme Kevin, Wasserman Stephen R, Emtage Spencer, Burley Stephen K and Reich Siegfried H. SGX523 is an exquisitely selective, ATP-competitive inhibitor of the MET receptor tyrosine kinase with antitumor activity in vivo. : Molecular cancer therapeutics. 20100324.